SPT Labtech Ltd. recently partnered with Alithea Genomics SA to integrate its firefly liquid handling platform with Alithea’s single-cell RNA-sequency technology to create a scalable and reproducible workflow for transcriptomics research.
Bruker Corp. shows no sign of slowing its buying binge, picking up Nanostring Technologies Inc. for $392.6 million in cash plus the assumption of certain liabilities in its seventh deal so far this year.
Nanostring entered bankruptcy in February and received a “stalking horse” bid of $220 million from private equity fund Patient Square Capital in March. Bruker won the competitive auction for Nanostring’s assets, besting the Patient Square bid by 78%. The deal is expected to close in early May.
10x Genomics Inc. launched its latest platform for single-cell analysis, the Chromium X Series, to cost-effectively "enable massively large-scale experiments," according to the company.
10x Genomics Inc. launched its latest platform for single-cell analysis, the Chromium X Series, to cost-effectively "enable massively large-scale experiments," according to the company. The system cuts the cost of single-cell analysis 83%, from 12 cents to 2 cents per cell, a significant step toward reducing the costs low enough to make genomic sequencing widely available.
10x Genomics Inc. began distribution of its new Visium Spatial Gene Expression for FFPE (formalin-fixed and paraffin-embedded) assay in the U.S., giving researchers access to whole transcriptome spatial gene expression across entire FFPE tissue samples. The assay allows researchers to overcome the challenges in transcriptome analysis created by FFPE processing.
Researchers around the globe are still struggling to understand the basic biology of COVID-19 infection, including how it works in the body and how to most effectively combat it. To aid them in their efforts under the weight of the ongoing pandemic, single-cell research tool company 10x Genomics Inc. has launched an updated version of its Chromium Single Cell Immune Profiling product.
SAN FRANCISCO – Single-cell analytics has the potential to replace all sorts of biology laboratory equipment, expects Pleasanton, Calif.-based 10x Genomics Inc.
Pleasanton, Calif.-based 10x Genomics Inc. priced its initial public offering to raise $390 million and then immediately climbed in the first hours of trading. The single-cell sequencing company had upwardly revised its share price range twice – and then priced above the latest one at $39 per share, heading to above $55 (NASDAQ:TXG) in its first few hours as a public company. That gave it a market cap of about $5.1 billion. 10x Genomics also took advantage of its momentum by boosting the number of shares to 10 million from the anticipated 9 million.
